GMED PE Ratio & Valuation,Is GMED Overvalued

GMED Relative Valuation

GMED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMED is overvalued; if below, it's undervalued.

Historical Valuation

Globus Medical Inc (GMED) is now in the Fair zone, suggesting that its current forward PE ratio of 21.54 is considered Fairly compared with the five-year average of 26.28. The fair price of Globus Medical Inc (GMED) is between 86.51 to 129.60 according to relative valuation methord.

Relative Value

Fair Zone

86.51-129.60

Current Price：86.66

Fair

21.50

11.64

EV/EBITDA

Globus Medical Inc. (GMED) has a current EV/EBITDA of 11.64. The 5-year average EV/EBITDA is 13.39. The thresholds are as follows: Strongly Undervalued below 5.78, Undervalued between 5.78 and 9.58, Fairly Valued between 17.19 and 9.58, Overvalued between 17.19 and 20.99, and Strongly Overvalued above 20.99. The current Forward EV/EBITDA of 11.64 falls within the Historic Trend Line -Fairly Valued range.

18.13

EV/EBIT

Globus Medical Inc. (GMED) has a current EV/EBIT of 18.13. The 5-year average EV/EBIT is 20.69. The thresholds are as follows: Strongly Undervalued below 10.41, Undervalued between 10.41 and 15.55, Fairly Valued between 25.83 and 15.55, Overvalued between 25.83 and 30.97, and Strongly Overvalued above 30.97. The current Forward EV/EBIT of 18.13 falls within the Historic Trend Line -Fairly Valued range.

3.77

Globus Medical Inc. (GMED) has a current PS of 3.77. The 5-year average PS is 4.86. The thresholds are as follows: Strongly Undervalued below 1.19, Undervalued between 1.19 and 3.03, Fairly Valued between 6.70 and 3.03, Overvalued between 6.70 and 8.54, and Strongly Overvalued above 8.54. The current Forward PS of 3.77 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Globus Medical Inc. (GMED) has a current P/OCF of 0.00. The 5-year average P/OCF is 14.87. The thresholds are as follows: Strongly Undervalued below -12.73, Undervalued between -12.73 and 1.07, Fairly Valued between 28.68 and 1.07, Overvalued between 28.68 and 42.48, and Strongly Overvalued above 42.48. The current Forward P/OCF of 0.00 falls within the Undervalued range.

69.43

P/FCF

Globus Medical Inc. (GMED) has a current P/FCF of 69.43. The 5-year average P/FCF is 41.49. The thresholds are as follows: Strongly Undervalued below -47.27, Undervalued between -47.27 and -2.89, Fairly Valued between 85.87 and -2.89, Overvalued between 85.87 and 130.26, and Strongly Overvalued above 130.26. The current Forward P/FCF of 69.43 falls within the Historic Trend Line -Fairly Valued range.

Globus Medical Inc (GMED) has a current Price-to-Book (P/B) ratio of 2.65. Compared to its 3-year average P/B ratio of 2.42 , the current P/B ratio is approximately 9.41% higher. Relative to its 5-year average P/B ratio of 3.12, the current P/B ratio is about -15.03% higher. Globus Medical Inc (GMED) has a Forward Free Cash Flow (FCF) yield of approximately 4.99%. Compared to its 3-year average FCF yield of 3.03%, the current FCF yield is approximately 65.06% lower. Relative to its 5-year average FCF yield of 2.84% , the current FCF yield is about 76.09% lower.

2.65

P/B

Median3y

2.42

Median5y

3.12

4.99

FCF Yield

Median3y

3.03

Median5y

2.84

Competitors Valuation Multiple

The average P/S ratio for GMED's competitors is 2.20, providing a benchmark for relative valuation. Globus Medical Inc Corp (GMED) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 22.91%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of GMED increased by 4.58% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 8.28 to 15.47.

The secondary factor is the Revenue Growth, contributed 22.91%to the performance.

Overall, the performance of GMED in the past 1 year is driven by Margin Expansion. Which is more sustainable.

22.91%

625.71M → 769.05M

Revenue Growth

86.84%

8.28 → 15.47

Margin Expansion

-105.17%

-543.58 → 28.10

P/E Change

4.58%

82.71 → 86.50

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Globus Medical Inc (GMED) currently overvalued or undervalued?

What is Globus Medical Inc (GMED) fair value?

GMED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Globus Medical Inc (GMED) is between 86.51 to 129.60 according to relative valuation methord.

How does GMED's valuation metrics compare to the industry average?

The average P/S ratio for GMED's competitors is 2.20, providing a benchmark for relative valuation. Globus Medical Inc Corp (GMED) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 22.91%, this premium appears sustainable.

What is the current P/B ratio for Globus Medical Inc (GMED) as of Dec 16 2025?

As of Dec 16 2025, Globus Medical Inc (GMED) has a P/B ratio of 2.65. This indicates that the market values GMED at 2.65 times its book value.

What is the current FCF Yield for Globus Medical Inc (GMED) as of Dec 16 2025?

As of Dec 16 2025, Globus Medical Inc (GMED) has a FCF Yield of 4.99%. This means that for every dollar of Globus Medical Inc’s market capitalization, the company generates 4.99 cents in free cash flow.

What is the current Forward P/E ratio for Globus Medical Inc (GMED) as of Dec 16 2025?

As of Dec 16 2025, Globus Medical Inc (GMED) has a Forward P/E ratio of 21.54. This means the market is willing to pay $21.54 for every dollar of Globus Medical Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Globus Medical Inc (GMED) as of Dec 16 2025?

As of Dec 16 2025, Globus Medical Inc (GMED) has a Forward P/S ratio of 3.77. This means the market is valuing GMED at $3.77 for every dollar of expected revenue over the next 12 months.

GMED Valuation